Weekly Oraxol for Second-Line Treatment of Metastatic, Recurrent Gastric Cancer

Share this content:

the Cancer Therapy Advisor take:

Moderate efficacy and favorable toxicity levels of Oraxol as a second-line chemotherapy treatment were observed in patients with metastatic or recurrent gastric cancer (GC), according to an article published online in the journal The Oncologist.

This study included two phases: phase I was to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of Oraxol (a chemotherapy drug consisting of paclitaxel and HM30181A, a P-glycoprotein inhibitor) and phase II was to evaluate efficacy and safety of Oraxol.

In phase I of the study, paclitaxel was orally administered in increasing doses of 90, 120, or 150 mg/m2 per day along with a fixed dose of 15mg per day of HM30181A. Oraxol was issued on days 1, 2, 8, 9, 15, and 16 (six times per cycle) every four weeks. In phase II of the study, the authors evaluated the efficacy and toxicity of Oraxol in the patients.

Results showed that the MTD could not be determined from phase I; however, the RP2D of oral paclitaxel was found to be 150 mg/m2 using toxicity and pharmacokinetic data.

In phase II, it was found that 9.3% of patients (4 out of 43) achieved a partial response level from treatment. The most common adverse effects (grade ≥ 3) caused by the drug were neutropenia and diarrhea.

The median progression-free survival was determined to be 2.6 months, while overall survival was calculated to be 10.7 months.

Imatinib is safe and effective in the treatment of patients with CML over a 10-year period.
Moderate efficacy and favorable toxicity levels of Oraxol as a second-line chemotherapy treatment were observed in gastric cancer.
Oraxol consists of paclitaxel and HM30181A, a P-glycoprotein inhibitor, to increase the oral bioavailability of paclitaxel.
READ FULL ARTICLE From theoncologist.alphamedpress.org

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs